We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
arGEN-X Opens Expansion Cohort in Phase 1b Study of ARGX-111
News

arGEN-X Opens Expansion Cohort in Phase 1b Study of ARGX-111

arGEN-X Opens Expansion Cohort in Phase 1b Study of ARGX-111
News

arGEN-X Opens Expansion Cohort in Phase 1b Study of ARGX-111

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "arGEN-X Opens Expansion Cohort in Phase 1b Study of ARGX-111"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

arGEN-X N.V. has announced that it has advanced ARGX-111, a best-in-class highly differentiated SIMPLE Antibody™ targeting c-MET driven malignancies, into the safety and efficacy expansion part of its Phase 1b study.

The objective of the expansion cohort is to further characterize the safety of ARGX-111 in cancer patients with MET amplified tumors, and to evaluate efficacy signals in order to select the indications to be studied in Phase 2 clinical development.

“We are pleased to have selected the dose of ARGX-111 to move forward into safety expansion cohort of the study. We based the selection on the results of the dose escalation portion of the study conducted in patients pre-screened for cancers with over-expression of c-Met,” commented Alain Thibault, M.D., Chief Medical Officer at arGEN-X.

Thibault continued, “Biological activity was illustrated especially in the context of MET amplification. We will recruit these types of patients for the upcoming expansion cohort and we expect to report interim data in the second half of 2016.”

The full data from the dose escalation part of the Phase 1b study will be presented at the upcoming 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, 29 May - 2 June, in Chicago, IL, USA.

Advertisement